Natus Medical Incorporated (Nasdaq:BABY) today announced financial results for the fourth quarter and full year ended December 31, 2011.
For the fourth quarter ended December 31, 2011, Natus reported revenue of $64.1 million, compared to $63.2 million reported in the comparable quarter of the previous year. The Company reported a loss of $17.3 million, or $0.60 per share, for the fourth quarter of 2011, compared with net income of $5.2 million, or $0.18 per diluted share, for the fourth quarter of 2010.
For the year ended December 31, 2011, Natus reported revenue of $232.7 million, compared to $218.7 million reported in 2010. Net loss was $11.7 million, or $0.41 per share for the year ended December 31, 2011, compared to net income of $11.9 million, or $0.41 per diluted share in 2010.
Results for the 2011 fourth quarter and full year include a $20 million non-cash goodwill impairment charge for the Company’s European operations.On a non-GAAP basis the Company reported net income of $4.1 million, or $0.14 per diluted share, for the fourth quarter of 2011, compared with net income of $7.0 million, or $0.24 per diluted share, for the fourth quarter of 2010, and net income of $14.0 million, or $0.47 per diluted share, for the full year 2011, compared with net income of $19.0 million, or $0.65 per diluted share, for the full year 2010. In commenting on the fourth quarter revenue results, Jim Hawkins, Chief Executive Officer of the Company said, “During the fourth quarter we experienced a strong rebound in our business with revenue of $64.1 million compared to $51.3 million reported for the third quarter and just shy of our $65 million guidance.” “I am pleased to report that recently acquired Embla Systems had an excellent quarter as did our newborn care group,” added Hawkins. “We continue to expect Embla to be accretive to earnings in 2012, adding approximately eight cents to non-GAAP earnings per share.”
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV